Epigenetic remodeling regulates transcriptional changes between ovarian cancer and benign precursors.
暂无分享,去创建一个
John Quackenbush | Henry W. Long | Brian Lawney | Myles Brown | John Quackenbush | M. Freedman | R. Drapkin | Fugen Li | T. Westerling | Brian P. Lawney | Matthew L Freedman | Ronny Drapkin | Fugen Li | Henry Long | Kevin M Elias | K. Elias | Thomas Westerling | Megan M Emori | Anna Budina-Kolomets | Emily MacDuffie | Michelle R Davis | Alexander Holman | Anna Budina-Kolomets | E. MacDuffie | M. Emori | Myles A. Brown | Alexander G. Holman
[1] S. Aerts,et al. Transcription factor MITF and remodeller BRG1 define chromatin organisation at regulatory elements in melanoma cells , 2015, eLife.
[2] R. Drapkin,et al. Overexpression of elafin in ovarian carcinoma is driven by genomic gains and activation of the nuclear factor kappaB pathway and is associated with poor overall survival. , 2010, Neoplasia.
[3] J. Marto,et al. Primary ex-vivo cultures of human fallopian tube epithelium as a model for serous ovarian carcinogenesis , 2009, Oncogene.
[4] Antonio Rosato,et al. Genome-wide association between YAP/TAZ/TEAD and AP-1 at enhancers drives oncogenic growth , 2015, Nature Cell Biology.
[5] Jennifer A. Mitchell,et al. Chromatin Dynamics in Lineage Commitment and Cellular Reprogramming , 2015, Genes.
[6] Marcin Imielinski,et al. Identification of focally amplified lineage-specific super-enhancers in human epithelial cancers , 2015, Nature Genetics.
[7] Clifford A. Meyer,et al. Cistrome: an integrative platform for transcriptional regulation studies , 2011, Genome Biology.
[8] G. Enikolopov,et al. Ovarian surface epithelium at the junction area contains cancer-prone stem cell niche , 2013, Nature.
[9] I. Clay,et al. YAP1 Exerts Its Transcriptional Control via TEAD-Mediated Activation of Enhancers , 2015, PLoS genetics.
[10] V. Velculescu,et al. Beyond genomics: critical evaluation of cell line utility for ovarian cancer research. , 2015, Gynecologic oncology.
[11] M. Loda,et al. A Comprehensive Analysis of PAX8 Expression in Human Epithelial Tumors , 2011, The American journal of surgical pathology.
[12] G. Schaffner,et al. DNA sequence recognition by Pax proteins: bipartite structure of the paired domain and its binding site. , 1993, Genes & development.
[13] R. Drapkin,et al. It's Totally Tubular....Riding The New Wave of Ovarian Cancer Research. , 2016, Cancer research.
[14] M. Noll,et al. Conservation of a large protein domain in the segmentation gene paired and in functionally related genes of Drosophila , 1986, Cell.
[15] R. Drapkin,et al. Modeling High-Grade Serous Carcinoma: How Converging Insights into Pathogenesis and Genetics are Driving Better Experimental Platforms , 2013, Front. Oncol..
[16] Gregory A. Wyant,et al. Transformation of the fallopian tube secretory epithelium leads to high-grade serous ovarian cancer in Brca;Tp53;Pten models. , 2013, Cancer cell.
[17] J. Mesirov,et al. Systematic investigation of genetic vulnerabilities across cancer cell lines reveals lineage-specific dependencies in ovarian cancer , 2011, Proceedings of the National Academy of Sciences.
[18] Jill P. Mesirov,et al. Targeted Tumor-Penetrating siRNA Nanocomplexes for Credentialing the Ovarian Cancer Oncogene ID4 , 2012, Science Translational Medicine.
[19] R. Drapkin,et al. Modeling high-grade serous ovarian carcinogenesis from the fallopian tube , 2011, Proceedings of the National Academy of Sciences.
[20] R. Drapkin,et al. YAP Induces High-Grade Serous Carcinoma in Fallopian Tube Secretory Epithelial Cells , 2015, Oncogene.
[21] David R. Kelley,et al. Differential gene and transcript expression analysis of RNA-seq experiments with TopHat and Cufflinks , 2012, Nature Protocols.
[22] Xiaohua Wu,et al. High Expressions of Lgr5 and ALDH1 in Primary Epithelial Ovarian Cancer Correlate with Advanced Tumor Stage and Grade as well as Poor Prognosis of the Patients , 2015, Gynecologic and Obstetric Investigation.
[23] Jun S. Song,et al. YY1 Regulates Melanocyte Development and Function by Cooperating with MITF , 2012, PLoS genetics.
[24] K. Guan,et al. YAP and TAZ: a nexus for Hippo signaling and beyond. , 2015, Trends in cell biology.
[25] Clifford A. Meyer,et al. Chromosome-Wide Mapping of Estrogen Receptor Binding Reveals Long-Range Regulation Requiring the Forkhead Protein FoxA1 , 2005, Cell.
[26] A. Tinker,et al. The role of the fallopian tube in ovarian cancer. , 2012, Clinical advances in hematology & oncology : H&O.
[27] D. Pisano,et al. Genome-wide analysis of Pax8 binding provides new insights into thyroid functions , 2012, BMC Genomics.
[28] P. Gruss,et al. Pax genes and their role in organogenesis. , 1999, Cancer research.
[29] M. Zannini,et al. A role for PAX8 in the tumorigenic phenotype of ovarian cancer cells , 2014, BMC Cancer.
[30] E. Winterhager,et al. Congenital hypothyroid female pax8-deficient mice are infertile despite thyroid hormone replacement therapy. , 2007, Endocrinology.
[31] E. Zammarchi,et al. Role for p300 in Pax 8 Induction of Thyroperoxidase Gene Expression* , 2000, The Journal of Biological Chemistry.
[32] R. Drapkin,et al. PAX8 Reliably Distinguishes Ovarian Serous Tumors From Malignant Mesothelioma , 2010, The American journal of surgical pathology.
[33] P Gruss,et al. Pax genes and their roles in cell differentiation and development. , 1996, Current opinion in cell biology.
[34] C. Sander,et al. Evaluating cell lines as tumour models by comparison of genomic profiles , 2013, Nature Communications.
[35] A. Jolma,et al. DNA-dependent formation of transcription factor pairs alters their binding specificity , 2015, Nature.
[36] C. Antonescu,et al. ETV1 is a lineage survival factor that cooperates with KIT in gastrointestinal stromal tumours , 2010, Nature.
[37] M. Goulding,et al. The molecular basis of the undulated/Pax-1 mutation , 1991, Cell.
[38] Karen D. Cowden Dahl,et al. In vivo tumor growth of high-grade serous ovarian cancer cell lines. , 2015, Gynecologic oncology.
[39] Sridhar Ramaswamy,et al. Bcl2 Regulation by the Melanocyte Master Regulator Mitf Modulates Lineage Survival and Melanoma Cell Viability , 2002, Cell.
[40] Joaquim Bellmunt,et al. Chromatin immunoprecipitation from fixed clinical tissues reveals tumor-specific enhancer profiles , 2016, Nature Medicine.
[41] S. Shah,et al. Type-Specific Cell Line Models for Type-Specific Ovarian Cancer Research , 2013, PloS one.
[42] R. Drapkin,et al. Primary culture and immortalization of human fallopian tube secretory epithelial cells , 2012, Nature Protocols.
[43] D. Katsaros,et al. The human KLK8 (neuropsin/ovasin) gene: identification of two novel splice variants and its prognostic value in ovarian cancer. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.
[44] C. Crum,et al. Serous Tubal Intraepithelial Carcinoma and the Dominant Ovarian Mass: Clues to Serous Tumor Origin? , 2009, The American journal of surgical pathology.
[45] W. Huber,et al. which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. MAnorm: a robust model for quantitative comparison of ChIP-Seq data sets , 2011 .
[46] Christopher P Crum,et al. Human epididymis protein 4 (HE4) is a secreted glycoprotein that is overexpressed by serous and endometrioid ovarian carcinomas. , 2005, Cancer research.
[47] M. Dimopoulos,et al. Expression and prognostic significance of kallikrein-related peptidase 8 protein levels in advanced ovarian cancer by using automated quantitative analysis , 2009, Thrombosis and Haemostasis.
[48] G. Daley,et al. A role for Lin28 in primordial germ cell development and germ cell malignancy , 2009, Nature.
[49] M. Noll,et al. Structure of the segmentation gene paired and the Drosophila PRD gene set as part of a gene network , 1986, Cell.
[50] G. Mills,et al. Elafin drives poor outcome in high grade serous ovarian cancers and basal-like breast tumors , 2013, Oncogene.